Zhang Qi, Iwami Daiki, Aramaki Osamu, Yakubo Shuji, Nishimura Ko, Ishige Atsushi, Watanabe Kenji, Matsuno Kenjiro, Shirasugi Nozomu, Niimi Masanori
Department of Surgery, Teikyo University, Itabashi-ku, Tokyo, Japan.
Transplantation. 2009 Jun 27;87(12):1787-91. doi: 10.1097/TP.0b013e3181a75917.
Sairei-to (TJ114), a 12-component Japanese herbal medicine, is used to treat immune-related diseases. We investigated the effects of oral administration of TJ114 in a murine model of cardiac transplantation with fully mismatched allografts. Untreated CBA mice rejected C57BL/6 hearts acutely (median survival time [MST], 7 days), whereas survival of allografts from mice given TJ114 was significantly prolonged (MST >100 days). Secondary CBA recipients of C57BL/6 hearts also had prolonged allograft survival (MST >100 days) after adoptive transfer of whole or CD4 splenocytes from primary CBA allograft recipients given TJ114. None of the individual components of TJ114 prolonged allograft survival, suggesting that its effects require administration of the combination agent. In mixed leukocyte cultures, proliferation of splenocytes from TJ114-treated CBA recipients was markedly suppressed compared with that of splenocytes from untreated mice, and interferon-gamma production was significantly reduced. Thus, in our model, TJ114 treatment induced hyporesponsiveness to cardiac allografts and generated CD4 regulatory cells.
柴苓汤(TJ114)是一种由12种成分组成的日本草药制剂,用于治疗免疫相关疾病。我们在完全不匹配的同种异体心脏移植小鼠模型中研究了口服TJ114的效果。未经治疗的CBA小鼠会急性排斥C57BL/6心脏(中位生存时间[MST],7天),而给予TJ114的小鼠的同种异体移植物存活时间显著延长(MST>100天)。在接受来自给予TJ114的原发性CBA同种异体移植物受体的全部或CD4脾细胞过继转移后,C57BL/6心脏的继发性CBA受体的同种异体移植物存活时间也延长(MST>100天)。TJ114的任何单一成分都不会延长同种异体移植物的存活时间,这表明其效果需要给予复方制剂。在混合淋巴细胞培养中,与未治疗小鼠的脾细胞相比,来自接受TJ114治疗的CBA受体的脾细胞增殖明显受到抑制,且干扰素-γ的产生显著减少。因此,在我们的模型中,TJ114治疗诱导了对心脏同种异体移植物的低反应性并产生了CD4调节性细胞。